Biocure Technology Inc.
Biocure Technology Inc.
Indice CSE:
Devise:
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE.X)
SEDAR Information
Information d'entreprise
Addresse
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaTéléphone
604-609-7146Fax
N/ACourriel
[email protected]URL
http://www.biocuretech.comDate d’inscription à la cote
Lundi, mai 10, 2010Relations avec les investisseurs
n/aVérificateur
DMCL Chartered Professional AccountantsCapitalisation
Capitalisation:
10444504Réservé à l'émission:
884059Company Officers
Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer
Communiqués de presse
Bulletins
23/10/2024
2024-1024 – Consolidation - Biocure Technology Inc. (CURE.X)
le 23 octobre/October 2024
Biocure Technology Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every nine (9) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 10,444,504 common shares.
The name and symbol will not change.
